CN115768786A - 多特异性蛋白质 - Google Patents

多特异性蛋白质 Download PDF

Info

Publication number
CN115768786A
CN115768786A CN202180044299.9A CN202180044299A CN115768786A CN 115768786 A CN115768786 A CN 115768786A CN 202180044299 A CN202180044299 A CN 202180044299A CN 115768786 A CN115768786 A CN 115768786A
Authority
CN
China
Prior art keywords
fap
seq
recombinant protein
binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044299.9A
Other languages
English (en)
Chinese (zh)
Inventor
N·里加蒙蒂
C·多姆克
V·P·卡拉波罗
P·A·特拉尔史密斯
V·勒维斯基
N·E·维丹玛基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of CN115768786A publication Critical patent/CN115768786A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180044299.9A 2020-05-14 2021-05-14 多特异性蛋白质 Pending CN115768786A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20174847 2020-05-14
EP20174847.2 2020-05-14
EP20181498.5 2020-06-22
EP20181498 2020-06-22
PCT/EP2021/062860 WO2021229067A1 (en) 2020-05-14 2021-05-14 Multispecific proteins

Publications (1)

Publication Number Publication Date
CN115768786A true CN115768786A (zh) 2023-03-07

Family

ID=75904957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044299.9A Pending CN115768786A (zh) 2020-05-14 2021-05-14 多特异性蛋白质

Country Status (13)

Country Link
US (2) US20240279290A1 (cg-RX-API-DMAC7.html)
EP (1) EP4149959A1 (cg-RX-API-DMAC7.html)
JP (1) JP7843711B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230022176A (cg-RX-API-DMAC7.html)
CN (1) CN115768786A (cg-RX-API-DMAC7.html)
AU (1) AU2021271129A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023049A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178785A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022017445A2 (cg-RX-API-DMAC7.html)
IL (1) IL298168A (cg-RX-API-DMAC7.html)
MX (1) MX2022014326A (cg-RX-API-DMAC7.html)
TW (1) TW202208408A (cg-RX-API-DMAC7.html)
WO (1) WO2021229067A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020402581A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
EP4387984A1 (en) * 2021-08-17 2024-06-26 Athebio AG Variants of ankyrin repeat domains
WO2023110983A1 (en) * 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2025163082A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2026150109A1 (en) * 2025-01-10 2026-07-16 Molecular Partners Ag Mesothelin-specific binding constructs and their use in radiotherapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
KR101268939B1 (ko) 2005-07-08 2013-05-30 유니버시티 오브 취리히 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
WO2012149439A2 (en) 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2906591A1 (en) 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US9458211B1 (en) 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
MY196882A (en) 2016-09-22 2023-05-08 Molecular Partners Ag Recombinant binding proteins and their use
CN110402255B (zh) * 2017-04-04 2022-12-02 豪夫迈·罗氏有限公司 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
AU2018363922B2 (en) 2017-11-08 2025-06-12 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to CD40 and EpCAM
US11242396B2 (en) * 2018-10-01 2022-02-08 Hoffmann-La Roche Inc. Bispecific antigen binding molecules comprising anti-FAP clone 212
KR20220016944A (ko) 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 개선된 안정성을 갖는 설계된 안키린 반복 도메인
JP2022535564A (ja) 2019-06-04 2022-08-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
CA3139164A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
EP3980452A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
AU2020402581A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
CN114945584A (zh) 2019-12-11 2022-08-26 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
MX2022013945A (es) 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
AU2021271131A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Recombinant CD40 binding proteins and their use
WO2022101458A1 (en) 2020-11-16 2022-05-19 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted cd40 agonists
AU2021403658A1 (en) 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use
US20240108746A1 (en) 2020-12-16 2024-04-04 Molecular Partners Ag Novel slow-release prodrugs
TW202300644A (zh) 2021-02-24 2023-01-01 中國大陸商杭州啟函生物科技有限公司 免疫細胞中的嵌合抗原受體
US20240317852A1 (en) 2021-03-09 2024-09-26 Molecular Partners Ag Novel darpin based cd33 engagers
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
KR20230169182A (ko) 2021-04-09 2023-12-15 몰리큘라 파트너스 아게 신규한 DARPin 기반 CD70 인게이저
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use

Also Published As

Publication number Publication date
CO2022017445A2 (es) 2023-02-16
TW202208408A (zh) 2022-03-01
BR112022023049A2 (pt) 2022-12-20
MX2022014326A (es) 2023-02-09
US20210395318A1 (en) 2021-12-23
US20240279290A1 (en) 2024-08-22
IL298168A (en) 2023-01-01
EP4149959A1 (en) 2023-03-22
JP7843711B2 (ja) 2026-04-10
US12331090B2 (en) 2025-06-17
KR20230022176A (ko) 2023-02-14
WO2021229067A1 (en) 2021-11-18
CA3178785A1 (en) 2021-11-18
JP2023528204A (ja) 2023-07-04
AU2021271129A9 (en) 2023-03-02
AU2021271129A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
US12331090B2 (en) Multispecific proteins
JP7587656B2 (ja) Pd-l1及びcd137に結合する抗体分子
US20240190999A1 (en) Multispecific proteins
JP6609724B1 (ja) 抗ヒト4−1bb抗体およびその使用
TWI839365B (zh) 間皮素及cd137結合分子
CN110392695B (zh) 针对cd127的抗体和多肽
JP6912386B2 (ja) 癌特異的なIL13Rα2を認識するCAR T細胞
JP2022176951A (ja) 標的化4-1bb(cd137)アゴニストとの併用療法
CN103492411B (zh) 突变体白介素-2多肽
JP2022536898A (ja) 新規il-15プロドラッグおよびその使用方法
EP4378962A2 (en) Anti-cancer fusion polypeptide
CN111727197A (zh) 抗pd-1抗体和治疗方法
WO2022272033A2 (en) Extended-release immune cell engaging proteins and methods of treatment
KR20180030898A (ko) Gdf15의 활성 감소용 제제
JP2023541996A (ja) SIRP1αキメラタンパク質の臨床投与
CN110177568A (zh) 用于治疗癌症的组合疗法
Salzman et al. Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis
KR20240058149A (ko) Vista 항원-결합 분자를 사용한 암의 치료 및 예방
CN121263440A (zh) 重组cd2结合蛋白及其用途
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
HK40016571B (en) Anti-human 4-1 bb antibodies and use thereof
HK40016571A (en) Anti-human 4-1 bb antibodies and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination